anthracycline

Type: Keyphrase
Name: anthracycline
First reported Sep 11 2014 - Updated Sep 11 2014 - 1 reports

PHILIPS : "Ultrasound Mediated Delivery with Critial-Organ Protection" in Patent Application Approval Process

By a News Reporter-Staff News Editor at Life Science Weekly -- A patent application by the inventors Raju, Balasundar Iyyavu ( Chester, NY ); Hall , Christopher Stephen ( Kirkland, WA ); Seip, Ralf ( Carmel, NY ); Erpelding, Todd Nicholas ( University ... [Published 4 Traders - Sep 11 2014]
First reported Sep 05 2014 - Updated Sep 05 2014 - 1 reports

Fertility May Be Preserved With Triptorelin Adjuvant to Chemotherapy in Younger Breast Cancer Patients

Long-term follow-up of a phase III clinical trial shows strong trends toward a greater likelihood of resuming menses and becoming pregnant when a luteinizing hormone-releasing hormone (LH-RH) analog is administered with chemotherapy in patients with breast ... [Published OncLive - Sep 05 2014]
First reported Sep 03 2014 - Updated Sep 03 2014 - 1 reports

5E Nausea

ALOXI Eisai RxSelective 5-HT3 receptor antagonist. Palonosetron (as HCl) 0.075mg/1.5mL, 0.25mg/5mL; IV inj; contains mannitol.Indications: Prevention of acute nausea and vomiting due to initial and repeat courses of moderately and highly emetogenic chemotherapy ... [Published HighBeam Research - Sep 03 2014]
First reported Sep 02 2014 - Updated Sep 02 2014 - 1 reports

Crystalline 4′-epidaunorubicin hydrochloride and use thereof

4′-epidaunorubicin hydrochloride is provided in a crystalline form which is stable and readily soluble. A process of producing the crystalline form includes crystallizing 4′-epidaunorubicin hydrochloride in a solvent system including (a) solvent A selected ... [Published Free Patents Online - Sep 02 2014]
Entities: Solvent, Solubility, Alcohol
First reported Sep 02 2014 - Updated Sep 02 2014 - 1 reports

Emerging Approaches in Acute Myeloid Leukemia

Figures:Hugo F. Fernandez, MDThe future of AML sees us aggressively treating this disease in induction and consolidation. Molecular targets are being discovered, and directed therapy will hopefully improve upon remission rates and overall survival in ... [Published The ASCO Post - Sep 02 2014]
First reported Aug 29 2014 - Updated Aug 29 2014 - 1 reports

ONLINE FIRST: HERA Trastuzumab Trial Shows Lower Risk of Cardiac Problems in HER2-Positive Breast Cancer Patients

BY KURT SAMSONWhen administered for up to two years, the monoclonal antibody trastuzumab did not increase heart-related problems in otherwise healthy women with early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer after chemotherapy ... [Published Oncology Times - Aug 29 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 1 reports

Prevention of Anthracycline-Induced Cardiotoxicity Challenges and Opportunities

Anthracycline compounds are major culprits in chemotherapy-induced cardiotoxicity, which is the chief limiting factor in delivering optimal chemotherapy to cancer patients. Although extensive efforts have been devoted to identifying strategies to prevent ... [Published Journal of the American College of Cardiology - Aug 25 2014]
First reported Aug 18 2014 - Updated Aug 19 2014 - 1 reports

Family Doctors in Driving Seat for Treating Cancer Survivors

General practitioners face a dilemma. In a recent survey ( Ann Intern Med . 2014;160:11-17 ), most reported being unfamiliar with the guidelines and uncomfortable treating adult survivors of childhood cancer; however, they can expect to see more such ... [Published General Medicine eJournal - Aug 18 2014]
Entities: Cancer, Radiation, Back Pain
First reported Aug 15 2014 - Updated Aug 15 2014 - 1 reports

A Novel Compound NSC745885 Exerts an Anti-Tumor Effect on Tongue Cancer SAS Cells In Vitro and In Vivo

by Yuan-Wu Chen, Hsu-Shan Huang, Yi-Shing Shieh, Kuo-Hsing Ma, Shing-Hwa Huang, Dueng-Yuan Hueng, Huey-Kang Sytwu, Gu-Jiun LinObjectiveOral squamous cell carcinoma (OSCC) is a prevalent cancer, especially in developing countries. Anthracyclines and their ... [Published Plosone.org - Aug 15 2014]
First reported Aug 12 2014 - Updated Aug 12 2014 - 1 reports

Compositions and methods of improving the tolerability of daunorubicin when given as orotate salt

This invention is in the field of anthracycline family of drugs. More particularly, it concerns converting daunorubicin hydrochloride to an orotate salt and providing methods of improving the tolerability of daunorubicin in animals by reducing the adverse ... [Published Free Patents Online - Aug 12 2014]
First reported Aug 06 2014 - Updated Aug 06 2014 - 1 reports

Findings from University of Central Florida Provide New Insights into Doxorubicin Therapy (Combination of Conventional Chemotherapeutics with...

Findings from University of Central Florida Provide New Insights into Doxorubicin Therapy (Combination of Conventional Chemotherapeutics with Redox-Active Cerium Oxide Nanoparticles-A Novel Aspect in Cancer Therapy)By a News Reporter-Staff News Editor ... [Published HispanicBusiness.com - Aug 06 2014]
First reported Jul 03 2014 - Updated Jul 03 2014 - 1 reports

Expanded EU approval sets Halaven on course

| SCRIPThe new indication means that it can be used in patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline ... [Published BioPortfolio - Jul 03 2014]

Quotes

"FIG. 3 is a flow chart providing more details of how operation according to FIG. 2, using the system of FIG. 1, could proceed; and"

More Content

All (30) | News (28) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
PHILIPS : "Ultrasound Mediated Delivery with Cr... [Published 4 Traders - Sep 11 2014]
Fertility May Be Preserved With Triptorelin Ad... [Published OncLive - Sep 05 2014]
5E Nausea [Published HighBeam Research - Sep 03 2014]
Crystalline 4′-epidaunorubicin hydrochloride an... [Published Free Patents Online - Sep 02 2014]
Emerging Approaches in Acute Myeloid Leukemia [Published The ASCO Post - Sep 02 2014]
ONLINE FIRST: HERA Trastuzumab Trial Shows Lowe... [Published Oncology Times - Aug 29 2014]
Prevention of Anthracycline-Induced Cardiotoxic... [Published Journal of the American College of Cardiology - Aug 25 2014]
Cardiovascular Toxicity Associated With Adjuvan... [Published General Medicine eJournal - Aug 21 2014]
Family Doctors in Driving Seat for Treating Can... [Published General Medicine eJournal - Aug 18 2014]
A Novel Compound NSC745885 Exerts an Anti-Tumor... [Published Plosone.org - Aug 15 2014]
Studies Assess Response to Platinum Therapy in ... [Published The ASCO Post - Aug 14 2014]
Strategies to overcome trastuzumab resistance i... [Published BMC - Aug 12 2014]
Global Hodgkins Lymphoma Therapeutics Market : ... [Published MarketResearch.com - Aug 12 2014]
Compositions and methods of improving the toler... [Published Free Patents Online - Aug 12 2014]
Merrimack Pharmaceuticals' (MACK) CEO Bob Mulro... [Published Seeking Alpha - Aug 11 2014]
Findings from University of Central Florida Pro... [Published HispanicBusiness.com - Aug 06 2014]
MicroRNA-140-5p as a tumor suppressor and sensi... [Published PharmCast - Jul 18 2014]
Expanded EU approval sets Halaven on course [Published BioPortfolio - Jul 03 2014]
TESARO's (TSRO) CEO Lonnie Moulder on Q1 2014 E... [Published The Street Latest - May 01 2014]
Variants of humanized immunomodulatory monoclon... [Published PharmCast - Apr 15 2014]
Targeting of bone marrow neovasculature [Published PharmCast - Apr 11 2014]
Tumor-initiating cells and methods of use [Published PharmCast - Apr 09 2014]
Clinigen Group Acquires Oncology Support Therap... [Published Business Wire Health News - Mar 31 2014]
Gem Pharmaceuticals nabs $4.5 mln [Published PE Hub Blog - Mar 19 2014]
Delivery system for cytotoxic drugs by bispecif... [Published PharmCast - Mar 02 2014]
New cap may prevent hair loss for patients unde... [Published KTRK TV - Feb 25 2014]
Pharmaceutical Research Interindividual Variabi... [Published BioPortfolio - Feb 23 2014]
Cell Therapeutics' Pixuvri gets final appraisal... [Published PharmaBiz - Jan 07 2014]
Dual variable domain immunoglobulins and uses t... [Published PharmCast - Dec 06 2013]
Cell Therapeutics concludes agreement with GKV-... [Published PharmaBiz - Dec 05 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Clinigen Group Acquires Oncology Support Therap... [Published Business Wire Health News - Mar 31 2014]
BURTON-ON-TRENT, England--(BUSINESS WIRE)--Clinigen Group plc (‘Clinigen’ or the ‘Group’) (LSE: CLIN) (AIM: CLIN) the specialty global pharmaceutical company today announces the acquisition of SAVENE® (dexrazoxane) from SpePharm AG, a majority owned affiliate ...
Gem Pharmaceuticals nabs $4.5 mln [Published PE Hub Blog - Mar 19 2014]
Gem Pharmaceuticals said Wednesday that it has received $4.5 million in funding. The investors were current board members Diane Hendricks and Karl Leo. Based in Birmingham, Alabama, Gem Pharmaceuticals is a clinical-stage biopharmaceutical company ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.